Patents Assigned to MedImmune Limited
  • Patent number: 9415117
    Abstract: A compound which is selected from A: B: and C: and salts and solvates thereof, as well as conjugates thereof with cell binding agent.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 16, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Publication number: 20160222113
    Abstract: The present invention provides antibodies and antigen-binding fragments that specifically bind PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders.
    Type: Application
    Filed: September 9, 2014
    Publication date: August 4, 2016
    Applicant: MedImmune Limited
    Inventors: Andrew Buchanan, Ross Stewart, Mathieu Chodorge
  • Patent number: 9403901
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: August 2, 2016
    Assignees: MedImmune, LLC, MedImmune Limited
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
  • Patent number: 9399073
    Abstract: A compound with the formula (I), wherein: R2 is of formula (II), where X is selected from the group comprising: OH, SH, CO2H, COH, N?C?O, NHNH2, CONHNH2, formula (A), formula (B), NHRN, wherein RN is selected from the group comprising H and C1-4 alkyl; RC1, RC2 and RC3 are independently selected from H and unsubstituted C1-2 alkyl; and either: R12 is selected from the group consisting of: (ia) C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; (ib) C1-5 saturated aliphatic alkyl; (ic) C3-6 saturated cycloalkyl; (id) formula (C), wherein each of R21, R22 and R23 are independently selected from H, C1-3 saturated alkyl, C2-3 alkenyl, C2-3 alkynyl and cyclopropyl, where the total number of carbon atoms in the R12 group is no more than 5; (ie) formula (D), wherein one of R25a and R25b is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 26, 2016
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Arnaud Tiberghien, Scott Jeffrey, Patrick Burke
  • Patent number: 9399641
    Abstract: A compound with the formula I wherein: R2 is of formula II where Q is selected from OH, SH and NRN, and RN is selected from H, methyl and ethyl, as well as drug-linkers and drug-conjugates made from this compound.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: July 26, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Publication number: 20160208222
    Abstract: The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.
    Type: Application
    Filed: September 2, 2014
    Publication date: July 21, 2016
    Applicant: MEDIMMUNE LIMITED
    Inventors: Xing CHENG, Danielle CARROLL, Matthew MCCOURT, Mark GALINSKI, Hong JIN
  • Patent number: 9387258
    Abstract: A compound, or a pharmaceutically acceptable salt or solvate thereof, or conjugates thereof, selected from the group consisting of formula wherein: (a) R10 is H, and R11 is OH, ORA, where RA is saturated C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is S02M, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation, or both M together are a divalent pharmaceutically acceptable cation.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 12, 2016
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • Patent number: 9387259
    Abstract: This invention relates to pyrrolobenzodiazepines (PBDs), in particular pyrrolobenzodiazepine dimers having a C2-C3 double bond and an aryl group at the C2 position in each monomer unit, and their inclusion in targeted conjugates. The differing substituent groups may offer advantages in the preparation and use of the compounds, particularly in their biological properties and the synthesis of conjugates, and the biological properties of these conjugates.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 12, 2016
    Assignees: SEATTLE GENETICS, INC., MEDIMMUNE LIMITED
    Inventors: Scott Jeffrey, Patrick Burke, Philip Wilson Howard
  • Patent number: 9388187
    Abstract: A compound with the formula I: wherein: R2 is of formula II: where A is a C5-7 aryl group, X is selected from the group comprising: NHNH2, CONHNH2, formula III, formula IV, and either: (i) Q1 is a single bond, and Q2 is selected from a single bond and —Z—(CH2)n—, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or (ii) Q1 is —CH?CH—, and Q2 is a single bond; R12 is a C5-10 aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C1-7 alkyl, C3-7 heterocyclyl and bis-oxy-C1-3 alkylene; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NHRR?, nitro, Me3Sn and halo; either: (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; (b) R10 and R11 form a nitrogen-carbon double bond between the n
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 12, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Publication number: 20160185837
    Abstract: This disclosure provides GIP/GLP-1 dual agonist polypeptides for the treatment of hypoglycemic conditions, e.g., type-2 diabetes.
    Type: Application
    Filed: August 15, 2014
    Publication date: June 30, 2016
    Applicant: Medimmune Limited
    Inventors: Maria Bednarek, Andie Collinson, David Hornigold, Siobhan O'Brien, Monika Papworth, Peter Ravn, Isabelle Sermadiras
  • Patent number: 9376440
    Abstract: Novel pyrrolobenzodiazepines (PBDs) having a (1-methyl-1H-pyrrol-3-yl)phenyl based amino acid residue and use thereof as antiproliferative agents are disclosed herein.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: June 28, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, David Edwin Thurston, Khondaker Mirazur Rahman
  • Publication number: 20160129108
    Abstract: The present invention provides therapeutic combinations featuring anti-CD73 antibodies (e.g., MEDI9447) and A2A receptor inhibitors and methods of using such combinations for reducing tumor-mediated immunosuppression.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 12, 2016
    Applicant: MedImmune Limited
    Inventors: Kris SACHSENMEIER, Erin Sult, Carl Hay, Edmund Poon
  • Patent number: 9321831
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 26, 2016
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Patent number: 9321774
    Abstract: A compound of formula (I) or a salt or solvate thereof, wherein the dotted double bond indicates the presence of a single or double bond between C2 and C3; R2 is selected from —H, —OH, ?O, ?CH2, —CN, —R, OR, halo, dihalo, ?CHR, ?CHRR?, —O—SO2—R, CO2R and COR; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R10 and R11 either together form a double bond, or are selected from H and QRQ respectively, where Q is selected from O, S and NH and RQ is H or C1-7 alkyl or H and SOxM, where x is 2 or 3, and M is a monovalent pharmaceutically acceptable cation; A is selected from (A1), (A2), (A3), (A4) or (A5) where X1 and Y1 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively; X2 and Y2 are selected from: CH and NH; CH and NMe; N and NMe; CH and S; N and S; N and O; and CH and O, respectively; Z1 is selected fr
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: April 26, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, David Edwin Thurston, Khondaker Mirazur Rahman, Peter William Taylor
  • Patent number: 9315575
    Abstract: Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: April 19, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventors: Phillip David Monk, Lutz Jermutus, Celia Patricia Shorrock, Ralph Raymond Minter
  • Patent number: 9315571
    Abstract: Specific binding members for Nerve Growth Factor (NGF), in particular anti-NGF antibody molecules, especially human antibody molecules, and especially those that neutralize NGF activity. Methods for using anti-NGF antibody molecules in diagnosis or treatment of NGF related disorders, including pain, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, other diseases of airway inflammation, diabetic neuropathy, cardiac arrhythmias, HIV, arthritis, psoriasis and cancer.
    Type: Grant
    Filed: January 24, 2006
    Date of Patent: April 19, 2016
    Assignees: Elan Pharma International Limited, MedImmune Limited
    Inventors: Ruth Franks, Andrew Grier Buchanan, Albert George Thom, Fraser Ewing Welsh, Philip Antony Bland-Ward, Matthew Alexander Sleeman, Carl Anthony Matthews, Celia Patricia Hart, Jon Eric Hawkinson
  • Patent number: 9284589
    Abstract: Specific binding members directed to eotaxin-1, in particular human antibodies and antibody fragments against human eotaxin-1 and especially those which neutralize eotaxin-1 activity. The antibodies VH and/or VL domain of the scFv fragment herein termed CAT-212 and of the IgG4 antibody herein termed CAT 213. One or more complementary determining regions (CDRs) of the CAT-212/-213 VH and/or VL domains, especially VH CRD3 in other antibody framework regions. Compositions containing specific binding members, and their use in methods of inhibiting or neutralizing eotaxin, including methods of treatment of the human or animal body by therapy.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: March 15, 2016
    Assignee: Medimmune Limited
    Inventors: Tristan John Vaughan, Alison Jane Wilton, Stephen Smith, Sarah Helen Main
  • Patent number: 9283274
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 15, 2016
    Assignee: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • Patent number: 9266894
    Abstract: A compound with the formula I wherein: R2 is of formula II where Q is selected from OH, SH and NRN, and RN is selected from H, methyl and ethyl, as well as drug-linkers and drug-conjugates made from this compound.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: February 23, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Patent number: 9255144
    Abstract: The present invention provides human, humanized and/or chimeric antibodies as well as fragments, derivatives/conjugates and compositions thereof with a specific binding affinity for interleukin-18. The invention includes the use of these antibodies for diagnosing and treating diseases associated with increased IL-18 activity, the latter in the form of a pharmaceutical composition.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: February 9, 2016
    Assignee: MedImmune Limited
    Inventors: Claire Dobson, Steven Lane, Philip Newton, Martin Schwickart, Ann-Charlott Steffen